Feihan Zhou
Overview
Explore the profile of Feihan Zhou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang J, Zhou F, Luo X, Fang Y, Wang X, Liu X, et al.
Cell Death Discov
. 2025 Mar;
11(1):84.
PMID: 40032852
Transcriptional dysregulation is a hallmark of cancer initiation and progression, driven by genetic and epigenetic alterations. Enhancer reprogramming has emerged as a pivotal driver of carcinogenesis, with cancer cells often...
2.
Liu X, Wang X, Ren J, Fang Y, Gu M, Zhou F, et al.
BMC Cancer
. 2025 Jan;
25(1):6.
PMID: 39754071
Background: Pancreatic cancer is a highly aggressive neoplasm characterized by poor diagnosis. Amino acids play a prominent role in the occurrence and progression of pancreatic cancer as essential building blocks...
3.
Fang Y, Liu X, Ren J, Wang X, Zhou F, Huang S, et al.
Microbiol Spectr
. 2024 Oct;
12(11):e0096224.
PMID: 39387592
Importance: We conducted a large sample-size pancreatic adenocarcinoma microbiome study using a novel microbiome sequencing method and two metabolomic assays. Two significant outcomes of our analysis are: (i) commensal opportunistic...
4.
Wang X, Yang J, Ren B, Yang G, Liu X, Xiao R, et al.
Genes Dis
. 2024 Sep;
11(6):101143.
PMID: 39253579
Pancreatic cancer, a highly fatal malignancy, is predicted to rank as the second leading cause of cancer-related death in the next decade. This highlights the urgent need for new insights...
5.
Wang X, Liu X, Xiao R, Fang Y, Zhou F, Gu M, et al.
Cancer Lett
. 2024 Jul;
598:217117.
PMID: 39019144
Cancer cells rewire metabolism to sculpt the immune tumor microenvironment (TME) and propel tumor advancement, which intricately tied to post-translational modifications. Histone lactylation has emerged as a novel player in...
6.
Liu X, Ren B, Fang Y, Ren J, Wang X, Gu M, et al.
J Transl Med
. 2024 Apr;
22(1):393.
PMID: 38685045
Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with high probability of recurrence and distant metastasis. Liver metastasis is the predominant metastatic mode developed in most pancreatic cancer cases,...
7.
Gu M, Ren B, Fang Y, Ren J, Liu X, Wang X, et al.
MedComm (2020)
. 2024 Feb;
5(2):e495.
PMID: 38374872
Epigenetic modifications are defined as heritable changes in gene activity that do not involve changes in the underlying DNA sequence. The oncogenic process is driven by the accumulation of alterations...
8.
Ren J, Ren B, Liu X, Cui M, Fang Y, Wang X, et al.
Cancer Lett
. 2024 Feb;
587:216649.
PMID: 38311052
Pancreatic cancer is a highly malignant solid tumor with a poor prognosis and a high mortality rate. Thus, exploring the mechanisms underlying the development and progression of pancreatic cancer is...
9.
Yang J, Ren B, Ren J, Yang G, Fang Y, Wang X, et al.
J Exp Clin Cancer Res
. 2023 Jun;
42(1):155.
PMID: 37370109
Background: Pancreatic ductal adenocarcinoma (PDAC) tends to undergo distant metastasis, especially liver metastasis, leading to a poor prognosis. Metabolic remodelling and epigenetic reprogramming are two important hallmarks of malignant tumours...